If the atogepant label is expanded, the drug will be the only gepant approved for the broad indication of prevention of both episodic and chronic migraine.
Yale headache specialist Christopher Gottschalk, MD, talks about the opportunities to make a marked difference in the quality of patients' lives.
The CGRP inhibitor class of injectable migraine preventive agents has a very favorable side effect profile but the drugs do come with some cautions, says Christopher Gottschalk, MD.
Opioid refills were reduced by ~40% in the 9 months following an initial prescription for rimegepant among patients with migraine, a new study found.
The migraine-specific oral gepants are proving effective across the continuum of migraine frequency. Dr Gottschalk talks about their shaky start.
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with headache specialist Peter McAllister, MD.
Gottschalk says CGRP inhibitors have made "...a life-changing transformation in how we think about and the kind of expectations we set for migraine treatment."
Christopher Gottschalk, MD, a leader in migraine research and clinical care, talks about what drew him to headache medicine early on and what it used to be like.
Individuals with migraine were found more likely to have IBS and IBS was more prevalent in those with migraine; both associations were statistically significant.
Findings for atogepant from the phase 3 PROGRESS study will form the basis of a submission by AbbVie to FDA for a label expansion in the US.